Category: biotech

.Veteran venture capital firm venBio has actually raised an additional half a billion bucks to purchase biotechs working on diseases with unmet necessity. The $528

.After announcing a period 3 launch based on positive midstage results, iTeos and GSK are actually lastly sharing the highlights from the period 2 TIGIT

.Zevra Therapies’ rare condition medication seems to be to be on the road to confirmation this fall after obtaining the backing of an FDA consultatory

.Otsuka Drug’s kidney health condition medicine has actually struck the major endpoint of a stage 3 test through showing in an acting review the decrease

.Bicara Therapeutics and also Zenas Biopharma have actually offered clean catalyst to the IPO market with filings that explain what recently public biotechs might look

.CEO David Ricks may find the firms establishing camping tents at basecamp behind Eli Lilly in an attempt to receive a foothold of the being

.After raising $213 million in 2023– some of the year’s most extensive exclusive biotech shots– Volume Biosciences is creating cuts.” In spite of our crystal

.As biotechs attempt to turn a new page in August, a minimum of three companies have shed personnel in attempts to shape on. To begin

.OncoC4 is taking AcroImmune– and its internal medical production capacities– under its wing in an all-stock merging.Both cancer cells biotechs were co-founded through OncoC4 CEO

.Zephyrm Bioscience is gusting towards the Hong Kong stock market, submitting (PDF) for an IPO to money period 3 tests of its tissue treatment in